We are live on ! Find out more
PSTV

Plus Therapeutics
PSTV

Delisted

PSTV was delisted on the 31st of July, 2026.

Back to rankings

5 hedge funds and large institutions have $1.12M invested in Plus Therapeutics in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $952K → $1.12M (+$164K)

0% more funds holding

Funds holding: 5 → 5 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PCM
Perkins Capital Management
Minnesota
+$420K
2
Jane Street
Jane Street
New York
+$70.1K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$70.1K
2
Renaissance Technologies
Renaissance Technologies
New York
-$43K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$11K
4
VF
Virtu Financial
New York
-$10K
5
UB
UMB Bank
Missouri
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
UB
26
UMB Bank
Missouri
– -$7K – –
VF
27
Virtu Financial
New York
– -$10K – –
1
2

PSTV Hedge Fund Activity: Q4 2017 in Review

5 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2017, worth a combined $1.12M — up 17% from $952K a quarter earlier.

Fund positioning in PSTV was balanced in Q4 2017: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Perkins Capital Management, adding an estimated $420K. The largest seller was Vanguard Group, cutting an estimated $70.1K.

  • 5 institutional investors held Plus Therapeutics (PSTV) as of Q4 2017, unchanged from Q3 2017.
  • Funds reported $1.12M of Plus Therapeutics stock for Q4 2017, up 17% quarter-over-quarter.
  • 1 fund opened new Plus Therapeutics positions in Q4 2017 and 1 closed out, a net change of 0 holders.
  • The largest Plus Therapeutics buyer in Q4 2017 was Perkins Capital Management, an estimated $420K added.
  • The largest Plus Therapeutics seller in Q4 2017 was Vanguard Group, an estimated $70.1K sold.

Based on aggregated 13F filings for Q4 2017.